Enterprise Value
329.7M
Cash
21.63M
Avg Qtr Burn
-9.215M
Short % of Float
0.06%
Insider Ownership
0.00%
Institutional Own.
9.93%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NBTXR3 + Cetuximab Details Head and neck cancer, Cancer | Phase 3 Interim Update | |
NBTXR3 + Immunotherapy Details Head and neck cancer, Cancer | Phase 3 Update | |
NBTXR3 Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
NBTXR3 + immunotherapy Details Cancer, Esophageal cancer | Phase 1/2 Data readout | |
NBTXR3 Details Cancer, Pancreatic cancer | Phase 1b Data readout | |
NBTXR3 Details Head and neck cancer, Cancer | Phase 1 Data readout | |
NBTXR3 + Anti-PD-1 Details Head and neck cancer, Cancer | Phase 1 Update |